公开(公告)号：US11014911B2

公开(公告)日：2021-05-25

申请号：US16774786

申请日：2020-01-28

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20160221989A1

公开(公告)日：2016-08-04

申请号：US14817416

申请日：2015-08-04

Applicant: Pfizer Inc.

Inventor： Sharanjeet Kaur Bagal ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Michelle Bich Tran-Dubé

IPC: C07D401/12 ,  A61K31/4439

CPC classification number: C07D401/12 ,  A61K31/4439

Abstract: The present invention relates to compounds of Formula I described herein and their pharmaceutically acceptable salts, and their use in medicine, in particular as Trk antagonists.

Abstract translation: 本发明涉及本文所述的式I化合物及其药学上可接受的盐，以及它们在医药中的用途，特别是作为Trk拮抗剂。

公开(公告)号：US20180044344A1

公开(公告)日：2018-02-15

申请号：US15664265

申请日：2017-07-31

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: C07D487/04 ,  C07D401/14

CPC classification number: C07D487/04 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US11773082B2

公开(公告)日：2023-10-03

申请号：US17235846

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

CPC classification number: C07D403/12 ,  A61P35/00 ,  C07D413/12 ,  C07B2200/07

Abstract: This invention relates to compounds of Formula (I)






and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20170197939A1

公开(公告)日：2017-07-13

申请号：US15300440

申请日：2015-04-01

Applicant: PFIZER INC.

Inventor： Sharanjeet Kaur Bagal ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Elizabeth Ann Lunney ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Robert Ian Storer ,  Joseph Scott Warmus

IPC: C07D401/14 ,  A61K31/4439 ,  C07D401/12

CPC classification number: C07D401/14 ,  A61K31/4439 ,  C07D401/12

Abstract: The present invention relates to compounds of Formula I and their prodrugs and pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

公开(公告)号：US09328096B2

公开(公告)日：2016-05-03

申请号：US14705272

申请日：2015-05-06

Applicant: PFIZER INC

Inventor： Sharanjeet Kaur Bagal ,  Jingrong Jean Cui ,  Samantha Elizabeth Greasley ,  Elizabeth Ann Lunney ,  Indrawan James McAlpine ,  Asako Nagata ,  Sacha Ninkovic ,  Kiyoyuki Omoto ,  Sarah Elizabeth Skerratt ,  Robert Ian Storer ,  Joseph Scott Warmus

IPC: A61P35/00 ,  C07D413/14 ,  A61P29/00 ,  C07D405/14 ,  A61K31/4439 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D405/14 ,  C07D413/14

Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.

Abstract translation: 本发明涉及式I化合物及其药学上可接受的盐，其中取代基如本文所述，及其在药物中的用途，特别是作为TrkA拮抗剂。

公开(公告)号：US09290496B2

公开(公告)日：2016-03-22

申请号：US14548749

申请日：2014-11-20

Applicant: PFIZER INC.

Inventor： Douglas Carl Behenna ,  Hengmiao Cheng ,  Sujin Cho-Schultz ,  Theodore Otto Johnson, Jr. ,  John Charles Kath ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Simon Paul Planken

IPC: A61K31/519 ,  C07D473/18 ,  A61P35/00 ,  A61K31/5377 ,  C07D498/10 ,  A61K31/5386 ,  C07D487/04 ,  A61K31/52 ,  C07D473/16 ,  C07D519/00

CPC classification number: C07D473/16 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/5386 ,  C07D473/18 ,  C07D519/00

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中Q，G，环A，环B，R1，R2，R3，R4，R5，R5a，R6，R7，R8，R9， R 11，R 12，R 13，R 14，R 15，R 16，R 17，R 18，R 19，R 20，R 21，R 22，R 23，R 24和m如本文所定义。 新型嘌呤衍生物可用于治疗哺乳动物中异常细胞生长，如癌症。 另外的实施方案涉及含有化合物的药物组合物和使用化合物和组合物治疗哺乳动物异常细胞生长的方法。

公开(公告)号：US12281127B2

公开(公告)日：2025-04-22

申请号：US18903345

申请日：2024-10-01

Applicant: PFIZER INC.

Inventor： Benjamin Joseph Burke ,  Jacob Cole Deforest ,  Asako Nagata ,  Simon Paul Planken ,  Jillian Elyse Spangler ,  Scott Channing Sutton ,  Hanna Maria Wisniewska ,  Shouliang Yang

IPC: C07D519/00 ,  A61K31/553 ,  A61P35/00

Abstract: The invention relates to compounds of Formula (I)-(III) and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds the present invention may be useful in the treatment, prevention, suppression and amelioration diseases, disorders and conditions such as cancers.

公开(公告)号：US20210261530A1

公开(公告)日：2021-08-26

申请号：US17235836

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US10800783B2

公开(公告)日：2020-10-13

申请号：US16251032

申请日：2019-01-17

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: A61K31/519 ,  A61K31/4375 ,  A61K31/4545 ,  C07D487/04 ,  C07D401/12 ,  C07D471/04 ,  C07D401/14

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.